ACCELERON PHARMA INC - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - February 27, 2020

Attached files

file filename
EX-10.22 - EXHIBIT 10.22 - ACCELERON PHARMA INCxlrn-20191231xex1022.htm
EX-10.19 - EXHIBIT 10.19 - ACCELERON PHARMA INCxlrn-20191231xex1019.htm
EX-10.21 - EXHIBIT 10.21 - ACCELERON PHARMA INCxlrn-20191231xex1021.htm
EX-31.2 - EXHIBIT 31.2 - ACCELERON PHARMA INCxlrn-20191231xex312.htm
EX-32.1 - EXHIBIT 32.1 - ACCELERON PHARMA INCxlrn-20191231xex321.htm
EX-21.1 - EXHIBIT 21.1 - ACCELERON PHARMA INCxlrn-20191231xex211.htm
EX-4.4 - EXHIBIT 4.4 - ACCELERON PHARMA INCxlrn-20191231xex44.htm
10-K - 10-K - ACCELERON PHARMA INCxlrn-20191231x10k.htm
EX-31.1 - EXHIBIT 31.1 - ACCELERON PHARMA INCxlrn-20191231xex311.htm


Exhibit 23.1

Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-8 No. 333-192789) pertaining to the Acceleron Pharma Inc. 2003 Stock Option and Restricted Stock Plan and the Acceleron Pharma Inc. 2013 Equity Incentive Plan,

(2)
Registration Statement (Form S-8 No. 333-198259) pertaining to the Acceleron Pharma Inc. 2013 Employee Stock Purchase Plan and the Acceleron Pharma Inc. 2013 Equity Incentive Plan,

(3)
Registration Statement (Form S-8 No. 333-203354) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan,

(4)
Registration Statement (Form S-8 No. 333-211867) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan,

(5)
Registration Statement (Form S-8 No. 333-219661) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan,

(6)
Registration Statement (Form S-3 No. 333-220522) of Acceleron Pharma Inc.,

(7)
Registration Statement (Form S-8 No. 333-223270) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan, and

(8)
Registration Statement (Form S-8 No. 333-229911) pertaining to the Acceleron Pharma Inc. 2013 Equity Incentive Plan;

of our reports dated February 27, 2020, with respect to the consolidated financial statements of Acceleron Pharma Inc. and the effectiveness of internal control over financial reporting of Acceleron Pharma Inc. included in this Annual Report (Form 10-K) of Acceleron Pharma Inc. for the year ended December 31, 2019.
 
 
/s/ Ernst & Young LLP
Boston, Massachusetts
February 27, 2020



ACCELERON PHARMA INC Reports